DXCM · Dexcom Inc
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 13, 2022; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $785.8M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Non-GAAP diluted net income per share non-GAAP | $1.26 | Six Months Ended June 30, 2026 | — |
| Non-GAAP diluted weighted-average shares outstanding non-GAAP | 384.1M | Six Months Ended June 30, 2026 | — |
| Non-GAAP gross profit non-GAAP | $1.6B | Six Months Ended June 30, 2026 | — |
| Non-GAAP net income non-GAAP | $485.4M | Six Months Ended June 30, 2026 | — |
| Non-GAAP operating income non-GAAP | $592.7M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DXCM
this stock
Dexcom Inc
|
$34.05B | +35.9% | +60.2% | 35.8 | 4.6% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$119.47B | -3.9% | +8.4% | 25.0 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -48.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 13, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DXCM | -1.4% | +28.0% | +22.9% | +8.1% | +35.9% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +0.6% | +24.7% | +11.7% | +6.0% | +24.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.